Arie Weber - Purple Biotech Independent Director

KTOV Stock  ILA 24.20  0.10  0.41%   

Director

Mr. Arie Weber serves as Independent Director at Kitov Pharma Ltd since January 22, 2017. He is a Member of Kitov Parent audit, compensation and investment committees. His work experience includes the following roles Chairman of the Board of Scorpio Investments Ltd, Chief Executive Officer of Alonei Meitar Ltd, Chairman of the Board of Inventec Investments Ltd, Manager of the Securities and Investments sector at United Mizrahi Bank, Director at Capital Point Ltd, Lapidoth Israel Oil Prospectors Corporationration Ltd, Sunny Communications Ltd, Mashabim United Mizrahi Bank Offerings Company Ltd, Tel Aviv Stock Exchange Ltd, Maalot Israel Rating Agency and Excellence Investment Management Company and Chairman at Tel Aviv Stock Exchange Clearing House and Bank Mizrahi Registration Company since 2017.
Age 68
Tenure 7 years
Phone972 3 933 3121
Webhttp://www.kitovpharma.com
Weber holds a Masters degree in Economics and Business Administration from Kharkov National University, Ukraine.

Purple Biotech Management Efficiency

The company has return on total asset (ROA) of (0.0915) % which means that it has lost $0.0915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9204) %, meaning that it generated substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 117 K in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Purple Biotech has a current ratio of 2.18, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Purple Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Purple Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Purple Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Purple to invest in growth at high rates of return. When we think about Purple Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Ytzhak EdelmanBezeq Israeli Telecommunication
64
Aaron NahumiAlony Hetz Properties
55
Ron MiloDelek Group
67
Ilan BiranBezeq Israeli Telecommunication
70
Itshak ForerAlony Hetz Properties
80
Binyamin GabbayB Communications
53
Ami BarlevBezeq Israeli Telecommunication
39
Micha ChorinDiscount Investment Corp
45
Doron TurgemanBezeq Israeli Telecommunication
49
Meir JacobsonDiscount Investment Corp
64
Gittit GubermanAlony Hetz Properties
61
Shimon DoronDelek Group
57
Ehud MezumanBezeq Israeli Telecommunication
62
Efraim HalevyAzrieli Group
82
Edith LuskyBezeq Israeli Telecommunication
66
Zeev VurembrandBezeq Israeli Telecommunication
66
Itzhar CiechanoverAzrieli Group
83
Naama EmanuelAlony Hetz Properties
33
Elad ZadokDiscount Investment Corp
35
Avraham HarelDelek Group
70
Amikam ShorerBezeq Israeli Telecommunication
49
Kitov Pharma Ltd, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. KITOV PHARMA operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people. Purple Biotech (KTOV) is traded on Tel Aviv Stock Exchange in Israel and employs 9 people.

Management Performance

Purple Biotech Leadership Team

Elected by the shareholders, the Purple Biotech's board of directors comprises two types of representatives: Purple Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Purple. The board's role is to monitor Purple Biotech's management team and ensure that shareholders' interests are well served. Purple Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Purple Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Itzhak Israel, Chief Executive Officer & Director
Steven Steinberg, Independent Director
Gil BenMenachem, Vice President - Business Development
Michael Schickler, Head of Clinical Operations
Philip Serlin, Independent Director
CPA MBA, Strategic Director
Arie Weber, Independent Director
Bertrand Liang, Chief Medical Officer
Yisrael Gewirtz, Internal Auditor
John Waymack, Chairman of the Board & Chief Medical Officer
Ran Tzror, Independent Director
Gil Efron, Deputy Chief Executive Officer, Chief Financial Officer
Simcha Rock, CFO, Director
Eric Rowinsky, Chairman of the Board
Moran SherfBlau, External Director
Ido Agmon, Independent Director
Gil CPA, Deputy CFO
Leah Bruck, Director
Isaac Israel, CEO Director
Revital SternRaff, Independent Director
Pinhas BarShmuel, Internal Auditor
Avraham BenTzvi, General Counsel, Secretary
Alain Zeitoun, External Director
Hadas Reuveni, Founder and Chief Technology Officer of TyrNovo (a subsidiary)

Purple Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Purple Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Purple Biotech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Purple Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Purple Biotech Stock. Highlighted below are key reports to facilitate an investment decision about Purple Biotech Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Purple Stock analysis

When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Global Correlations
Find global opportunities by holding instruments from different markets
Please note, there is a significant difference between Purple Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Purple Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Purple Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.